<DOC>
	<DOC>NCT02542436</DOC>
	<brief_summary>This study will focus on participants in the United Kingdom (UK) to collect local data on the effectiveness and safety of bevacizumab (Avastin) in the treatment of metastatic colorectal cancer in normal clinical use.</brief_summary>
	<brief_title>Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in Normal Clinical Use in the UK Population</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Have been diagnosed with metastatic colorectal cancer (mCRC) Have a Performance Status (PS) of 02, according to the Eastern Cooperative Oncology Group (ECOG) criteria at initiation of bevacizumab treatment Be chemotherapynaive at diagnosis of mCRC or have relapsed more than 12 months after receiving adjuvant chemotherapy for early stage colorectal cancer Have received standard fluoropyrimidinebased chemotherapy for firstline treatment of mCRC with or without bevacizumab Have sufficient medical records available for assessment of eligibility at the Christie Hospital National Health Service (NHS) Trust, Manchester, United Kingdom For Cohort 1 (post CDF funding availability): patients between 20102013 who received bevacizumab with firstline chemotherapy For Cohort 2 (pre Cancer Drugs Fund [CDF] funding availability): patients propensity matched to cohort 1 between 20052008 who did not receive bevacizumab with firstline chemotherapy Subjects with metastatic colorectal cancer, who have received bevacizumab via a clinical trial Subjects with metastatic colorectal cancer, whose medical records are not complete enough to confirm eligibility for the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>